Hormonal
Dual GLP-1/Glucagon receptor agonists (e.g., Cotadutide, Oxyntomodulin) promote weight loss by combining appetite suppression (GLP-1) with increased energy expenditure (Glucagon).
Drugs like Cotadutide combine two hormones: GLP-1 (which reduces appetite) and Glucagon (which increases energy expenditure). This dual action can lead to weight loss, potentially greater than GLP-1 alone. These are daily injections. Be aware of potential gastrointestinal side effects and monitor heart rate, as glucagon can increase heart rate. Discuss with your doctor if this mechanism is appropriate for your health profile.
The combination of lipolytic and thermogenic actions of glucagon with the anorectic and insulinotropic actions of GLP-1 is crucial for the targeted management of obesity... Oxyntomodulin reduces food intake and enhances energy expenditure by activating both GLP-1 receptors and glucagon receptors.
Why this rating
Based on small-scale clinical trials (e.g., 65 subjects for Cotadutide) and animal studies; evidence is promising but less robust than GLP-1/GIP data.
Source
New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review
Agni Kakouri et al. · Pharmaceuticals · 2021
DOI 10.3390/ph14090869
More from this paper
- Combination incretin therapies (GLP-1/GIP, GLP-1/Glucagon, or GLP-1/GIP/Glucagon) produce superior weight loss and glycemic control compared to monotherapy GLP-1 receptor agonists by targeting multiple hormonal pathways simultaneously.Moderate
- Combining GLP-1 receptor agonists with SGLT2 inhibitors produces additive weight loss by reducing caloric intake (GLP-1) and increasing caloric excretion via glucosuria (SGLT2).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →